N/A
Completed N=224
Optimisation of the Treatment of Infectious Bursitis
Olecranon Bursitis · Patellar Bursitis
Source: ClinicalTrials.gov NCT01406652 ↗
Enrolled (actual)
224
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcomePrimary: Overall Costs of the Combined Surgical and Medical Treatment — 6881; 11178 Swiss Francs
Summary
The study investigates prospectively the cost-savings related to a one-stage bursectomy (debridement, drainage and closure at the same time) versus two-stage bursectomy (debridement, left open and closure at a second time) of severe bursitis among hospitalized patients for surgical treatment of septic bursitis.
We suppose that the one-stage bursectomy reveals similar recurrence rates but is associated with a significant shortening of hospital stay, consumption of resources and increased patient satisfaction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Costs of the Combined Surgical and Medical Treatment |
6881; 11178 | — |
| SECONDARY Number of Participants With Post-surgical Wound Dehiscence |
2; 10 | — |
Eligibility Criteria
Inclusion Criteria
- Age >18 years
- Hospitalized for bursectomy for septic bursitis
Exclusion Criteria
- Bacteraemic diseases
- Presence of another concomitant infection requiring antibiotics
- Presence of osteosynthesis material beneath the bursitis
- Septic bursitis outside of the elbow or the knee
- Severe immune suppression (transplantation, HIV with Cluster of Differentiation cell count <200 cells/mm3, immune suppressive treatment with equivalence of more than 15 mg of prednisone daily ).
- Recurrent septic bursitis episodes
Data sourced from ClinicalTrials.gov (NCT01406652). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.